Tailoring Adjunct Glycine Therapy in Schizophrenia

Funded Activity Summary

‘Glycine’ is an amino acid that can be purchased ‘over the counter’ at health food shops in Australia. Although traditionally administered as a dietary supplement, recently there has been considerable excitement in the psychiatric community due to its ability to improve schizophrenia symptoms when administered in conjunction with mainstream medications. However, two issues need to be resolved in order for glycine to be employed as a routine therapy in schizophrenia. Firstly, this treatment is only effective in some patients, and we have no way of determining which patients will benefit from glycine. Secondly, there are both theoretical reasons and experimental evidence that glycine administration can cause severe impairment for some individuals. Thus although there is great potential for glycine to ease the burden of schizophrenia symptoms, these two issues need to be resolved before this possibility can be actualised. Theoretical considerations, supported by pilot research of the investigators, point to the view that schizophrenia patients’ baseline glycine level is the critical factor that determines whether a patient will benefit or be impaired by glycine therapy. This thesis offers a testable means with which to resolve the above limitations to the use of glycine. The purpose of the current research program is thus to provide the basis for rational prescription of glycine as an additional therapeutic tool in schizophrenia.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2013

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $447,353.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Paediatrics not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Cognition | Complementary Medicine | EEG | Neuropharmacology | Schizophrenia

Related Links